Diabetes, obesity, GLP-1 therapies, cardiovascular and renal disease: approvals, pricing and access.
Diabetes, obesity, GLP-1 therapies, cardiovascular and renal disease: approvals, pricing and access.
A CVS Health white paper using Aetna claims data finds GLP-1s offset their full cost to plan sponsors only at $350 per month — well below current employer prices of …
Pelacarsen reduced lipoprotein(a) (Lp(a)) by 78% in a Phase III trial of more than 8,300 adults yet produced no reduction in major adverse cardiovascular events, raising questions about whether lowering …
An international trial of 702 randomized adults found left bundle branch pacing (LBBP) lowered the hazard of death, heart failure hospitalization or pacing-induced cardiomyopathy by 59% (hazard ratio 0.41) versus …
A matched cohort of 52,330 women aged 45 to 59 found no excess risk of heart attack, stroke, blood clots, or death over 12 years — with no meaningful difference …
Novo Nordisk began distributing oral semaglutide 25 mg (Wegovy tablets) in Mexico’s private market on November 11, after COFEPRIS approval in August. The same day, an update to the national …
Costa Rica’s social security fund is running technical studies to choose a GLP-1 molecule for patients with diabetes, with obesity to follow. A diabetes decision is expected in November, as …
Resolution 1447/2026 replaces the 2021 primary-care essential medicines list behind Argentina’s Remediar programme with a list focused on vascular disease, leaving other conditions to provincial procurement after a transition kit …
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo …
The FDA has approved insulin efsitora alfa-gobe (Onswik), Eli Lilly’s once-weekly basal insulin for adults with type 2 diabetes, making it the second such agent cleared in the US and …
Mercado Livre launched prescription medicine sales in São Paulo on 25 September 2026, including GLP-1 drugs and antibiotics, as pharmacy chain shares fell sharply and Abrafarma said it would formally …
You must be logged in to post a comment.